On July 11 at 10 AM, Thomas O’Linn, Senior Procurement Policy Analyst, Acquisition Policy Division of the Office of Government-Wide Policy at the General Services Administration, will be speaking at

During the webinar, Stephen and Greg will discuss the critical distinctions between Average Manufacturer Price (AMP) and Weighted Average Manufacturer Price (WAMP) and their implications for both brand and generic drugs. Additionally, they will highlight and discuss a top issue impacting each program, providing you with the insights needed to stay compliant in this evolving landscape.